Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
Want to see BOLD full AI Analyst Report?
Top Page
Boundless Bio Inc.
(NASDAQ:BOLD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(18.11% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily pressured by weak financial performance (no revenue, large sustained losses, and significant ongoing cash burn) and a negative corporate event that adds a sizable cash outflow. Technicals are only mildly supportive (neutral momentum and price still above longer-term averages), while valuation is constrained by a negative P/E and no dividend yield.
Positive Factors
Differentiated science
A focused platform targeting ecDNA represents a structural competitive advantage: it addresses a distinct mechanism linked to oncogene amplification and resistance. This scientific differentiation can sustain durable IP, attract partnerships, and create high barriers to entry versus general oncology approaches.
Negative Factors
No revenue
The company generates no revenue and relies entirely on financing to fund R&D. That structural absence of operating income means long-term viability depends on capital markets, milestones, or partnerships. Persistent losses erode equity and raise funding risk over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated science
A focused platform targeting ecDNA represents a structural competitive advantage: it addresses a distinct mechanism linked to oncogene amplification and resistance. This scientific differentiation can sustain durable IP, attract partnerships, and create high barriers to entry versus general oncology approaches.
Read all positive factors
Boundless Bio Inc. (BOLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.90M
Dividend YieldN/A
Average Volume (3M)178.65K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue GrowthN/A
EPS Growth15.42%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.50
Shares Outstanding22,464,111
10 Day Avg. Volume162,533
30 Day Avg. Volume178,649
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.27
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap1.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-51.48
Enterprise Value/Ebitda-1.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-2.38
Revenue Forecast (FY)N/A
Boundless Bio Inc. Business Overview & Revenue Model
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor o...
How the Company Makes Money
null...
Boundless Bio Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -1.25M | -1.09M | 0.00 | 0.00 | 0.00 |
| EBITDA | -56.81M | -62.30M | -64.28M | -53.84M | -45.53M | -24.62M |
| Net Income | -55.99M | -58.20M | -65.36M | -49.43M | -45.90M | -25.21M |
Balance Sheet | ||||||
| Total Assets | 140.97M | 157.06M | 206.41M | 129.89M | 76.83M | 113.72M |
| Cash, Cash Equivalents and Short-Term Investments | 92.85M | 107.58M | 152.11M | 120.75M | 66.72M | 73.03M |
| Total Debt | 48.29M | 49.03M | 47.63M | 2.19M | 5.18M | 377.00K |
| Total Liabilities | 54.59M | 58.41M | 55.77M | 256.98M | 158.53M | 151.91M |
| Stockholders Equity | 86.38M | 98.65M | 150.64M | -127.08M | -81.70M | -38.19M |
Cash Flow | ||||||
| Free Cash Flow | -47.60M | -47.21M | -63.38M | -47.49M | -40.66M | -25.28M |
| Operating Cash Flow | -47.10M | -46.66M | -60.84M | -46.85M | -39.60M | -23.25M |
| Investing Cash Flow | 49.33M | 37.80M | -26.10M | -38.26M | 16.13M | -59.28M |
| Financing Cash Flow | 141.00K | 141.00K | 89.82M | 97.90M | 126.00K | 105.53M |
Boundless Bio Inc. Technical Analysis
Positive
1.27
Price Trends
1.34
Positive
1.26
Positive
1.23
Positive
Market Momentum
0.03
Positive
45.10
Neutral
14.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Positive. The current price of 1.27 is below the 20-day moving average (MA) of 1.51, below the 50-day MA of 1.34, and above the 200-day MA of 1.23, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 14.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLD.
Boundless Bio Inc. Risk Analysis
Boundless Bio Inc. disclosed 81 risk factors in its most recent earnings report. Boundless Bio Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Boundless Bio Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $269.13M | -1.52 | -124.06% | ― | ― | 39.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $26.08M | -1.05 | -70.57% | ― | -100.00% | 21.30% | |
45 Neutral | $33.17M | -0.84 | -139.47% | ― | 43.88% | 14.79% | |
44 Neutral | $31.90M | -0.45 | -53.60% | ― | ― | 15.42% | |
42 Neutral | $6.27M | -1.40 | -92.74% | ― | 360.39% | 35.61% | |
40 Underperform | $33.66M | -1.38 | 280.42% | ― | 4.35% | 20.37% |
* Healthcare Sector Average
BOLD
Boundless Bio Inc.
1.42
-0.24
-14.46%
PLUR
Pluri
2.60
-1.91
-42.35%
CLGN
Collplant Holdings
0.45
-1.59
-77.94%
ALXO
ALX Oncology Holdings
1.99
1.58
385.37%
ALGS
Aligos Therapeutics
5.60
-0.03
-0.53%
BRNS
Barinthus Biotherapeutics
0.69
-0.14
-17.13%
Boundless Bio Inc. Corporate Events
Business Operations and Strategy
Boundless Bio Terminates Major Long-Term San Diego Lease
Negative
Apr 13, 2026
On April 13, 2026, Boundless Bio, Inc. agreed to terminate its lease for approximately 80,168 square feet of laboratory and office space at 10955 Alexandria Way in San Diego, a lease that had originally been scheduled to run through October 31, 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.